Published in Health Business Week, February 16th, 2007
The agreement provides a research license and an option for an exclusive license to develop and commercialize tubulysin-polymer conjugates.
"With this agreement, Insert has secured proprietary rights to one of the most potent anti-cancer compounds known," said Edward L. Jacobs, Insert's CEO and president. "The major challenge to...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.